Work

Abstract CT006: Phase 1 DKY709A12101C study in patients with advanced solid tumors treated with DKY709, an IKZF2 degrader, alone or in combination with PDR001, a PD-1 inhibitor

Year: 2026

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2026-ct006

Authors: Elena Garralda, Chia-Chi Lin, Takafumi Koyama, Brigette Ma, Melissa Johnson, Martin Schuler, Martin Wermke, Justin Gainor, Raj Gopal, Debby Long, Jaeyeon Kim, Divyasree Maddirala, Anhthu Dang, Xin Yang, Mark Awad

Institutions: Vall d'Hebron Institute of Oncology, National Taiwan University Hospital, National Cancer Centre Japan, Prince of Wales Hospital, Sarah Cannon, Essen University Hospital, Technische Universität Dresden, Massachusetts General Hospital, Novartis (United States), Dana-Farber Cancer Institute

Language: English

Topic: Protein Degradation and Inhibitors

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W7154711325

Cites:

Cited by: 1

Related to: